Stockscreener 앱 받기
1.86
3.33%
0.06
전일 마감가:
$1.80
열려 있는:
$1.93
하루 거래량:
114.36K
Relative Volume:
4.52
시가총액:
$10.29M
수익:
-
순이익/손실:
$-14.29M
주가수익비율:
-0.4662
EPS:
-3.99
순현금흐름:
$-12.27M
1주 성능:
+14.81%
1개월 성능:
+21.01%
6개월 성능:
-42.77%
1년 성능:
-66.73%
1일 변동 폭
$1.86
$2.01
1주일 범위
$1.45
$2.01
52주 변동 폭
$1.412
$5.80
Aprea Therapeutics Inc Stock (APRE) Company Profile
명칭
Aprea Therapeutics Inc
전화
215-948-4119
주소
3805 OLD EASTON ROAD, DOYLESTOWN, MA
APRE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
APRE
Aprea Therapeutics Inc
|
1.86 | 8.95M | 0 | -14.29M | -12.27M | -3.99 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Aprea Therapeutics Inc Stock (APRE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-12-28 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-12-16 | 개시 | Berenberg | Buy |
| 2020-09-29 | 재개 | JP Morgan | Neutral |
| 2020-06-22 | 개시 | H.C. Wainwright | Neutral |
| 2020-04-21 | 개시 | Robert W. Baird | Outperform |
| 2019-10-28 | 개시 | JP Morgan | Neutral |
| 2019-10-28 | 개시 | Morgan Stanley | Equal-Weight |
| 2019-10-28 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Aprea Therapeutics Inc 주식(APRE)의 최신 뉴스
Wedbush Forecasts Lower Earnings for Aprea Therapeutics - Defense World
Petro-Victory Energy Corp. Announces Short Term Loan - Barchart.com
Strathcona Resources Ltd. Reports First Quarter 2025 Financial and Operating Results, Announces Quarterly Dividend and Investment in MEG Energy Corp. - Barchart.com
Aprea Therapeutics Reports Q1 2025 Progress and Financials - TipRanks
NoticeGO-TO DEVELOPMENTS HOLDINGS INC., GO-TO SPADINA ADELAIDE SQUARE INC., FURTADO HOLDINGS INC., and OSCAR FURTADO, File No. 2022-8 - Barchart.com
RBC Global Asset Management Inc. Announces RBC ETF Cash Distributions For May 2025 - Barchart.com
Strathcona Resources Ltd. Announces Sale of Montney Business for $2.84 Billion and Acquisition of Hardisty Rail Terminal - Barchart.com
BIG ROCK BREWERY INC. ANNOUNCES RESULTS OF ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS - Barchart.com
This Under-The-Radar Cancer Biotech Reports 21% Tumor Shrinkage: Analysts See 600%+ Upside - Barchart.com
GFL Environmental Inc. Announces Results From Annual General Meeting Of Shareholders - Barchart.com
Aprea (APRE) Reports Q1 Revenue Drop Amid Clinical Progress | AP - GuruFocus
APRE Reports Decrease in Cash Reserves by End of Q1 2025 | APRE Stock News - GuruFocus
Aprea Therapeutics Reports Promising Q1 2025 Results - TipRanks
Aprea Therapeutics reports Q1 EPS (66c) vs. (67c) last year - TipRanks
Aprea Therapeutics, Inc. SEC 10-Q Report - TradingView
Aprea Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Enphase Energy Announces IQ Batteries Qualify for New York Battery Incentive Program - The Manila Times
Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update - TradingView
Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update - GlobeNewswire Inc.
Stocks In Play: Knight Therapeutics Inc - Barchart.com
NRx Pharmaceuticals (NASDAQ: NRXP) To Report Q1 2025 Results On May 15 - Barchart.com
Aprea Therapeutics Inc expected to post a loss of 86 cents a shareEarnings Preview - TradingView
Stocks In Play: Galiano Gold Inc. - Barchart.com
Stocks In Play: Illumin Holdings Inc. - Barchart.com
LifeSpeak Inc. Announces First Quarter 2025 Results - Barchart.com
Stocks In Play: Knight Therapeutics Inc. - Barchart.com
Adicet Bio Advances Two Breakthrough Therapies: Key Clinical Data Coming in 2025 for Lupus and Cancer Programs - Stock Titan
Larimar Therapeutics Reports Q1 2025 Results and Advances Nomlabofusp Development - MyChesCo
LPL Financial LLC Makes New $53,000 Investment in Aprea Therapeutics, Inc. (NASDAQ:APRE) - Defense World
LPL Financial LLC Sells 14,965 Shares of Veren Inc. (NYSE:VRN) - Defense World
Stocks In Play: Boyd Group Services Inc. - Barchart.com
Repare Therapeutics Inc.'s (NASDAQ:RPTX) Shares Bounce 30% But Its Business Still Trails The Industry - simplywall.st
Prelude Therapeutics Unveils Promising Preclinical Data on Novel Cancer Therapies - MyChesCo
Halda Therapeutics Announces Appointment of Eyal Attar, MD, as Chief Medical Officer - Business Wire
Century Therapeutics Hosts Live Fireside Chat on Groundbreaking Cell Therapy Advances - MyChesCo
APRE stock touches 52-week low at $1.5 amid market challenges - Investing.com Australia
Adicet Bio Strengthens Board with Ex-Johnson & Johnson VP: Strategic Move for Cell Therapy Pioneer - Stock Titan
Adicet Bio Appoints Michael Grissinger to the Board of Directors - Business Wire
INOVIO to Showcase Breakthrough Data on INO-3107 at Major Industry Conferences - MyChesCo
Aprea Therapeutics Welcomes New Chief Medical Officer to Spearhead Clinical Pipeline Expansion - MSN
Aprea Therapeutics Advances ACESOT-1051 Clinical Trial with Key Patient Dosing - MSN
TIBSOVO's Continued Success Solidifies Its Position as a Leader in IDH1 Mutant Space | DelveInsight - The Malaysian Reserve
APRE stock touches 52-week low at $1.74 amid market challenges - Investing.com
Aprea Therapeutics CEO Gilad Oren acquires $10,110 in stock By Investing.com - Investing.com India
Aprea Therapeutics President/CEO Gilad Oren Acquires 5,500 Shares - TradingView
Aprea Therapeutics CEO Gilad Oren acquires $10,110 in stock - Investing.com
Breaking Down Early Signs and Symptoms of Head and Neck Cancer - Curetoday
Biotech Alert: Searches spiking for these stocks today - TipRanks
Aprea doses HPV+ HNSCC subject in cohort 5 of APR-1051 trial - Yahoo
Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Up 28.0% in March - Defense World
Aprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 Trial - TradingView
Aprea Therapeutics Inc (APRE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.54%
7.58%
자본화:
|
볼륨(24시간):